Why this matters 1 Oral GLP-1 changes the access equation Approved in December 2025, Wegovy pill (oral semaglutide) offers a once-daily, non-injectable option for people living with obesity or overweightremoving a major barrier to long-term adherence
It works to support the production of both collagen and elastin, addressing skin aging by improving both structure and resilience
[DOI] [PubMed] [Google Scholar] 593.Franklin I., Gromada J., Gjinovci A., Theander S., Wollheim C.B
Those who did not discontinue therapy achieved a 0.4 percentage point drop in HbA1c vs
JAMA 2021 American Diabetes Association Standards of Care in Diabetes 2024: Obesity and Weight Management FDA: Medications Containing Semaglutide and Tirzepatide Marketed for Type 2 Diabetes or Weight Loss Lincoff AM et al
To assess input resistance, we measured the voltage deflection amplitudes at the end of responses to small hyperpolarizing rectangular current pulse steps, lasting 500 ms and ranging from 0 to 50 pA
